HEALTH● LOWAug 30 · Aug 30, 2026, 7:01 PM
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Seeking Alpha Tech · global
Tenax has identified a benefit in a sicker patient subgroup, despite missing its primary endpoint in a Phase 3 trial. This finding could indicate specific efficacy for a targeted patient population.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoInfluenza, leptospirosis emerge as major killers this season in KeralamThe HinduHEALTH43m agoClimate change increases dengue risk in Keralam; cases may rise by 20% by 2040, says studyThe HinduHEALTHBREAKING55m agoFiji declares national crisis as HIV infects one in every 60 adultsThe Independent WorldHEALTH57m agoADHD is linked to almost 50% increase in gut problemsEuroNews [en]